Lineage Cell Therapeutics (LCTX) Gross Profit Growth (3y) (2014 - 2026)
Lineage Cell Therapeutics (LCTX) Gross Profit Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 9.20% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.09% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 299.84% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 45.27% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 803.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 59.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 80.79% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -29.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.86% |
| Mar 31, 2026 | -8.71% |
| Dec 31, 2025 | 53.38% |
| Sep 30, 2025 | 9.98% |
| Jun 30, 2025 | -14.35% |
| Mar 31, 2025 | -33.83% |
| Dec 31, 2024 | 41.20% |
| Sep 30, 2024 | 42.79% |
| Jun 30, 2024 | 52.18% |
| Mar 31, 2024 | 68.97% |
| Dec 31, 2023 | 96.62% |
| Sep 30, 2023 | 31.93% |
| Jun 30, 2023 | 115.17% |
| Mar 31, 2023 | 75.42% |
| Dec 31, 2022 | 17.49% |
| Sep 30, 2022 | 82.71% |
| Jun 30, 2022 | 86.20% |
| Mar 31, 2022 | 80.54% |
| Dec 31, 2021 | 10.94% |
| Sep 30, 2021 | 10.71% |